The GLP-1 medicines semaglutide and tirzepatide do not alter disease-related pathology, behaviour or cognitive function in 5XFAD and APP/PS1 mice

• Egile Nagusiak: Leticia Forny Germano (Egilea), Jacqueline A. Koehler (Egilea), Laurie L. Baggio (Egilea), Fiona Cui (Egilea), Chi Kin Wong (Egilea), Nikolaj Rittig (Egilea), Xiemin Cao (Egilea), Dianne Matthews (Egilea), Daniel J. Drucker (Egilea)
• Formatua: Liburua
• Argitaratua: Elsevier, 2024-11-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Objective: The development of glucagon-like peptide-1 receptor (GLP-1R) agonists for the treatment of type 2 diabetes and obesity has been accompanied by evidence for anti-inflammatory and cytoprotective actions in the heart, blood vessels, kidney, and brain. Whether GLP-1R agonists might be useful...